Cancer results I certainly did not raise expectations about cancer results on the 9th. When folks raised in Jan waiting on patents, or the company announces in Feb, it is going to announce " preliminary results" in the spring, was enough to tell me don't expect much. I think they have known for a long time how their cancer antibodies are going to test in animal models, in both their Prp and Fas Receptor. The company continues to hold back information and in my view has not been transparant with its shareholders.
One reason might be "Biogen", under their agreement with Biogen posted on Sedar in October 2010, Biogen has the option in Section 2.2 " Option to Expand Licensed Field".
Section 2.21 Option Right. Amorfix hereby grants to Biogen Idec, the right (Option Right) to expand the indications covered by the licenced field on the following terms:
(1) Notice to Partner. In the Event that a "Qualified Study" is completed for any compostion that would qualify as a licensed product Amorfix shall provide in writing to Biogen.
More to that in the agreement, nevertheless Biogen has an option to exercise any other licenced products once a" Qualified Study" is completed. The process is furthered defined in the agreement.
I don't know Amorfix's reasons for slowing Cancer study results (Qualified Studies) , Alzhemiers results, might be as leverage wtih Biogen, I do however think that unlock the Biogen key and we will have our answer.